Drug Discovery World

JULY 25, 2024

Who: The US is home to the majority of the top 20 biotechnology companies, including Amgen, Gilead Sciences, Thermo Fisher Scientific, Vertex Pharmaceuticals and Regeneron Pharmaceuticals. The company is now pursuing a pipeline of mRNA vaccines for cancer, several of which are at the Phase II stage.

Government 130

Government Vaccine Marketing Pharmaceuticals 130

Drug Discovery World

MARCH 13, 2024

According to Statista, revenue in this sector is expected to grow at an annual rate of 6.77%, resulting in a market volume of US$2,208m by 2028 1. Singapore is among a few countries worldwide whose pharmaceutical export value far exceed the import value. UK-based molecular diagnostics group Yourgene operates in Singapore.

Government 173

Government Science Pharmaceuticals Vaccine 173

Drug Discovery World

AUGUST 8, 2023

In the global pharmaceuticals market, India ranks third worldwide for production by volume and the domestic pharmaceutical market is expected to reach US$120-130 billion by 2030 1. Similarly, The Times of India says that branded generic medicines have “long fuelled India’s pharmaceutical exports” 4.

Research 130

Research Pharmacy Pharmaceuticals Government 130

The Pharma Data

JANUARY 9, 2021

This growth primarily reflects increased sales of contract development and manufacturing (CDMO) services to pharmaceutical and biotechnology innovators and government/non-government organization (NGO) customers, as well as higher product sales. • Anthrax Vaccines. Adjusted Net Income (1).

Government 52

Government Vaccine Production Licensing 52

Codon

SEPTEMBER 29, 2024

2028 Over the next year, the scientific community ferociously interrogated the model. The average pass rate of phase I trials went up by 5 percent. Their pipelines were bursting with promising candidates, and their success rates in clinical trials were astronomical compared to the industry standard of just a few years back.

Engineering 125

Engineering Virus DNA Therapies 125

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. BNT162 mRNA-based Vaccine Program. Protease Inhibitor Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52